Threat Reversal Abnormality in Patients With Anxiety Disorders

Anxiety Disorder Clinical Trial

Official title:

Research on Threat Reversal Abnormality and Underlying Neural Mechanisms in Patients With Anxiety Disorders

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06232369
• Other study ID #: 82201672
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 2024
• Est. completion date: September 2025

Study information

• Verified date: February 2024
• Source: Shenzhen Kangning Hospital
• Contact: Jingchu Hu, Dr.
• Phone: (+86)15603072635
• Email: hujingchu[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to explore the flexibility of threat control and underlying neural mechanism based on the threat reversal paradigm (a highly validated new paradigm where threat learning and inhibition are required) in patients with anxiety disorders (mainly generalized anxiety disorder). The hypotheses are: 1. Threat reversal abilities are hypothesized to be impaired in patients with anxiety disorders compared to healthy normal subjects, which are assumed to be associated with anxiety symptoms. 2. The neural mechanism underlying threat reversal abnormalities in patients with anxiety disorders is hypothesized to involve the prefrontal cortex, amygdala, and hippocampus. 3. The repetitive stimulation to the core brain regions of threat reversal is assumed to improve threat reversal abilities and anxiety symptoms of patients.

Description:

In this study, there are three sub-trials in combination with skin conductance response (SCR), functional magnetic resonance imaging (fMRI), and non-invasive neuromodulation techniques to uncover the abnormal threat reversal in anxiety disorder at behavioral and neural levels. Participants in the first trial will learn the threat of emotional faces based on the Pavlovian conditioned fear learning paradigm; their neural activities in the hypothesized brain regions will be obtained via brain imaging equipment. The researchers will compare the differences among three groups (one patient group, two healthy control groups with different anxiety level) on performance in the threat reversal task, and their neural activities and brain functional connectivity characteristics, in order to reveal the potential behavioral threat reversal abnormalities and core associated brain regions underlying threat reversal. Participants in the second trial will be given the same learning paradigm and brain imaging equipment as in the first, but with repetitive stimulation intervention on the core brain regions determined in study 1. Using a double-blind randomized controlled experiment, the participants will be divided into three groups (active stimulation + patient, sham stimulation + patient, and sham stimulation + healthy control). The researchers will compare the behavioral differences in the threat reversal task after active and sham stimulation. Participants in the third trial will be given the same study design and intervention as the second trial, but for eight weeks. Finally, the researchers will retest and compare the improvement in threat reversal abilities and anxiety symptoms to see the long-term clinical effects of the intervention.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 190
• Est. completion date: September 2025
• Est. primary completion date: September 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria for patient participants:

Clinical diagnosis of anxiety disorders (by psychiatrists using the structured clinical interview for DSM-IV-TR (SCID) with reference to the diagnostic criteria for GAD according to the ICD-10)

Exclusion Criteria for patient participants:

1. A history of serious cardiovascular, cerebrovascular diseases, stroke, or other neurological disorders, a history of gastrointestinal diseases.

2. Severe hearing or vision impairments.

3. Metallic implants in the body, such as non-removable dentures, stents, metal plates, joint metal replacements, etc.

4. Claustrophobia.

5. Acute or chronic diseases or infections.

6. Pregnancy or breastfeeding.

7. Smoking or drinking alcohol within 24 hours before the experiment.

8. Previous participation in similar experiments conducted by this institution.

Inclusion Criteria for healthy control participants:

1. No physical diseases or mental disorders.

2. No claustrophobia.

3. No hereditary diseases.

4. No medication history or smoking history.

5. Females not pregnant and not in their menstrual period.

6. Normal vision or corrected vision, no smoking, drinking alcohol, or taking medication within 24 hours prior to the experiment.

7. No previous participation in similar experiments.

Related Conditions & MeSH terms

• Anxiety Disorder
• Anxiety Disorders
• Anxiety State

Intervention

Device:
• Active repetitive deep transcranial magnetic stimulation (dTMS)
Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation. The intervention will employ the H7 coil that is accurately delivered to the intended target by an optic navigation and a deep pulse protocol at 90% of the tested threshold for 15-minute stimulation duration.
• Sham repetitive deep transcranial magnetic stimulation (dTMS)
Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation. The intervention will employ the H7 coil that is placed on the scalp to mimic the sensation and sounds of the actual treatment but without letting the magnetic field reach the brain tissue for 15-minute duration.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Shenzhen Kangning Hospital	The National Natural Science Foundation of China (NSFC)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in participants' skin conductance response (SCR)	The level of SCR will be assessed for each experiment trial as the base-to-peak amplitude difference in skin conductance of the largest deflection (in micro-siemens; pS) in the 0.5-4.5-slatency window after stimulus onset.	Baseline; every week (assessed weekly up to 8 weeks from the date of last intervention session)
Primary	Changes in the prefrontal cortex measured with fMRI	Changes in the difference in blood oxygenation level dependent (BOLD) signals in the prefrontal cortex before and after the intervention.	Baseline; once per week (assessed weekly up to 8 weeks from the date of last intervention session)
Primary	Changes in the amygdala measured with fMRI	Changes in the difference in blood oxygenation level dependent (BOLD) signals in the amygdala before and after the intervention.	Baseline; once per week (assessed weekly up to 8 weeks from the date of last intervention session)
Primary	Changes in the hippocampus measured with fMRI	Changes in the difference in blood oxygenation level dependent (BOLD) signals in the hippocampus before and after the intervention.	Baseline; once per week (assessed weekly up to 8 weeks from the date of last intervention session)
Secondary	Changes in the State-Trait Anxiety Scale (STAI)	The STAI assesses the current state of anxiety and relatively stable aspects of anxiety proneness, each subscale consisting of 20 items. Each item is rated on a 4-point Likert scale, ranging from "Not at all" to "Very much". Higher summed scores in subscales indicate greater state anxiety and trait anxiety.	Baseline; once per week (assessed weekly up to 8 weeks from the date of last intervention session); 3 months (assessed at the week after 3 months from the last intervention session)
Secondary	Changes in the Intolerance of Uncertainty Scale-12 (IUS-12)	The IUS measures individuals' emotional, cognitive, and behavioral responses or tolerance to uncertain situations, consisting 12 items. Each item is rated on a 5-point Likert scale, ranging from "Not at all characteristic of me" to "Entirely characteristic of me". Higher summed total scores suggest a higher level of intolerance of uncertainty.	Baseline; once per week (assessed weekly up to 8 weeks from the date of last intervention session); 3 months (assessed at the week after 3 months from the last intervention session)
Secondary	Changes in the Anxiety Sensitivity Index (ASI)	The ASI measures the extent to which individuals are sensitive to their own anxiety symptoms, consisting 12 items. Each item is rated on a 5-point Likert scale, ranging from "Not at all characteristic of me" to "Entirely characteristic of me". Higher summed total scores indicate greater anxiety sensitivity.	Baseline; once per week (assessed weekly up to 8 weeks from the date of last intervention session); 3 months (assessed at the week after 3 months from the last intervention session)